Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders
Botulinum neurotoxins (BoNTs) are used in the treatment of many neurological disorders. The primary structure of BoNTs shows a high degree of homology with the tetanus neurotoxin, the toxoid of which is used as a vaccine. Because of the potential cross-reactivity between these toxins, we investigated the effects of Botulinum neurotoxin A (BoNT/A) and tetanus toxoid on peripheral blood mononuclear cells (PBMC) and the corresponding serum antibody levels, in twenty patients who had been treated with BoNT/A. We observed very low PBMC immunostimulation by BoNT/A at the tested dose (15 units/ml), as demonstrated by the low lymphocyte proliferation, and the absence of detectable antibodies cross-reacting with tetanus. However, exposure of PBMC from tetanus-sensitized patients to both neurotoxins showed that BoNT/A exerted a co stimulatory effect on tetanus-stimulated cells. Interestingly, in flow cytometry analysis, BoNT/A seemed to also alter the ratio of naïve (CD45RA): memory/effector (CD45RO) T lymphocyte subsets, in favour of CD45RO. These preliminary data give a new insight on the potential immune crossreactivity between the two antigens. In view of the wide use of both neurotoxins, these immunotoxic effects merit a more detailed investigation. © 2012 Bentham Science Publishers.
Showing items related by title, author, creator and subject.
Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus-infected patients is associated with the possession of HLA B51 Bogdanos, D. P.; Lenzi, M.; Okamoto, M.; Rigopoulou, E. I.; Muratori, P.; Ma, Y.; Muratori, L.; Tsantoulas, D.; Mieli-Vergani, G.; Bianchi, F. B.; Vergani, D. (2004)Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected ...
Efficacy of an AS03 A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs De Vleeschauwer, A. R.; Baras, B.; Kyriakis, C. S.; Jacob, V.; Planty, C.; Giannini, S. L.; Mossman, S.; Van Reeth, K. (2012)We used the pig model of influenza to examine the efficacy of an AS03 A-adjuvanted split H5N1 (A/Indonesia/05/2005) vaccine against challenge with a low pathogenic (LP) H5N1 avian influenza (AI) virus (duck/Minnesota/1525/1981) ...
Validated analysis of HIF-1α expression in cancer cells using a controlled and comparative immunoassay Ioannou, M.; Mylonis, I.; Kouvaras, E.; Papamichali, R.; Daponte, A.; Paraskeva, E.; Simos, G.; Koukoulis, G. K. (2010)The immunoreactivity of hypoxia inducible factor 1 α (HIF-1α) has been considered a reliable indicator of the HIF-1 pathway activation in tissue hypoxia. However, HIF-1α immunoreactivity has been evaluated with different ...